Unlike traditional chemotherapy, radioligand therapy's toxicity may be inversely correlated with tumor volume. In low-burden disease, fewer cancer cells act as a 'sink' for the drug, potentially leading to higher radiation exposure and side effects in healthy, PSMA-expressing tissues like salivary glands.

Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.

Radioligand therapy has a unique toxicity profile, described as 'the gift that keeps on giving,' where side effects can worsen even after the treatment course is complete. This contrasts with chemotherapy like docetaxel, where a patient's quality of life often rebounds and improves once the drug is stopped.

An experienced leader's ultimate due diligence for a radiopharmaceutical company was not the science on paper, but a single human scan. This image proves the drug goes to the tumor and not healthy organs, visually confirming the therapeutic window and de-risking the entire platform in one compelling piece of data.

Alpha-emitting radiopharmaceuticals physically destroy tumor cells, creating a cloud of debris that acts as a signal for the immune system. This "neoantigenic storm" helps T-cells identify and attack cancer, making checkpoint inhibitors more effective by providing a clearer target.

A practical method to monitor radioligand therapy is a post-treatment SPECT scan. Since the therapeutic agent is radioactive, a simple planar scan about 24 hours after injection can visually confirm where the drug was delivered. This provides real-time feedback, beyond PSA levels, to potentially adapt treatment.

Historically, intratumoral therapy was limited by the physical difficulty of reaching tumors. The rise of a new discipline, Interventional Oncology, has largely solved this access problem. The critical bottleneck is now the lack of drugs specifically designed and optimized for local delivery and sustained retention within the tumor.

Rhenium emits both beta particles (for therapy) and gamma rays (for imaging). This unique property allows Plus Therapeutics to see exactly where the drug goes and calculate the precise radiation dose absorbed by the tumor, effectively making every patient a well-controlled, single-subject study.

Perspective Therapeutics' approach is not to target a tumor in a specific organ, but to target a receptor (SSTR2) expressed on various tumors like neuroendocrine, breast, or lung cancer. This receptor-focused strategy creates broader applicability for a single drug, moving beyond traditional organ-based cancer definitions.